Kulkarni Samarth 4

What Happened Samarth Kulkarni, CEO of CRISPR Therapeutics (CRSP), had 20,625 restricted stock units convert/vest on March 14, 2026 (reported as a derivative exercise/conversion). Following vesting, 10,349 shares were sold in an open-market transaction on March 16, 2026 at $48.26 per share, generating $499,443. The filing also reports the 20,625-share conversion/disposition entry tied to the RSU settlement.

Key Details

• Transaction dates: RSU conversion/vesting on 2026-03-14; open-market sale on 2026-03-16; Form 4 filed 2026-03-17 (appears timely).
• Sale: 10,349 shares at $48.26 = $499,443 (open-market; disposition code S).
• Conversion/Vesting: 20,625 shares reported as converted/exercised (code M) on 2026-03-14.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes:
  • F1: These shares remain subject to a lock-up agreement with underwriters for the issuer’s convertible senior notes due 2031.
  • F2–F4: The shares stem from a March 14, 2025 RSU grant for 82,500 shares (one-quarter, 20,625, vested 3/14/2026).
  • F3: The sale of 10,349 shares was mandated to cover tax withholding under the Company’s RSU Settlement Policy (i.e., not a discretionary trade).

Context This was a routine vesting and mandated sell-to-cover for tax withholding following RSU vesting (not a separate discretionary sale). The conversion/vesting and the sell-to-cover are commonly reported together; note that some or all converted shares remain subject to a lock-up per the filing.